Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2005
10/06/2005US20050222412 Antibiotic; bactericides
10/06/2005US20050222410 Inhibitors of histone deacetylase
10/06/2005US20050222409 Preparation of levofloxacin and forms thereof
10/06/2005US20050222408 Administering to a tuberculosis patient a therapeutically effective amount of N-(4-methoxybenzyl)-5-nitrofuran-2-carboxamide or other derivatives of heterocyclic amides
10/06/2005US20050222398 Glycopeptide conjugates and uses thereof
10/06/2005US20050222395 New peptide derivatives
10/06/2005US20050222387 Smac-peptides as therapeutics against cancer and autoimmune diseases
10/06/2005US20050222386 Biomolecule transduction motif sim-2-btm and the use thereof
10/06/2005US20050222312 Antioxidant and antimicrobial agents and methods of use thereof
10/06/2005US20050222275 Use of dmso in the treatment of neurodegenerative diseases caused by prions
10/06/2005US20050222274 Hyperforin halogenated derivatives, the use thereof and formulations containing them
10/06/2005US20050222273 Treatment of female sexual dysfunction
10/06/2005US20050222272 Method for treating autism
10/06/2005US20050222271 Novel amorphous form of memantine hydrochloride
10/06/2005US20050222270 Prolonged administration of NMDA antagonist drug and safener drug to create improved stable neural homeostasis
10/06/2005US20050222269 Use of deprenyl compounds to treat viral infections and reduce tissue damage associated therewith
10/06/2005US20050222268 Administering a compound for inhibiting cation exchange as hypotensive agents
10/06/2005US20050222267 Solution based methacholine formulations
10/06/2005US20050222266 2-indanylamino derivatives for the therapy of chronic pain
10/06/2005US20050222265 Ophthalmic solution
10/06/2005US20050222264 Anti-rhinovirus active agents
10/06/2005US20050222263 Compositions against stress-related diseases and methods for treating stress-related diseases
10/06/2005US20050222262 Novel NIDDM regimen
10/06/2005US20050222261 2-[2-(4-{2-[ethyl(2-fluorobenzyl)amino]-2-oxoethoxy}phenyl)ethoxy]benzoic acid; peroxisome proliferator-activated receptors alfa agonist; antidiabetic, hypotensive agent; obesity, elevated VLDL (Very Low Density Lipoproteins) and reduced HDL (High Density Lipoprotein) concentrations
10/06/2005US20050222260 (2S)-2-amino-a-{[2-(ethanimidoylamino) ethyl]thio}butanoic acid, a nitric oxide synthase inhibitor, in stabilized pharmaceutical dosage forms
10/06/2005US20050222259 Methods of activating PPAR-alpha nuclear receptors in mammals
10/06/2005US20050222258 Pharmaceuticals comprising shikonins as active constituent
10/06/2005US20050222254 Sulfonamide compounds for the treatment of neurodegenerative disorders
10/06/2005US20050222253 Anti-cancer nitro- and thia-fatty acids
10/06/2005US20050222252 Use of cis-Epoxyeicosantrienoic acids and inhibitors of soluble epoxide hydrolase to reduce pulmonary infiltration by neutrophils
10/06/2005US20050222251 Dual inhibition of cyclooxygenase-2 and carbonic anhydrase
10/06/2005US20050222250 Curcumin for the prevention and/or treatment of tissue damage
10/06/2005US20050222249 Softgel of NLKJ for treating prostate diseases
10/06/2005US20050222248 3'-hydroxy-dihydrodaidzein, 5-hydroxy-O-demethylangolesin; for treating hormone dependent conditions and other diseases and disorders; anticarcinogenic agents; menopausal syndrome; osteoporosis; rheumatic diseases; atherosclerosis; premenstrual syndrome; coronary artery spasm; vascular diseases
10/06/2005US20050222247 Chroman derivatives
10/06/2005US20050222246 Utilizing 3,4-dihydro-2, 2-dimethyl-2H-naphtho [1,2-b]pyran-5, 6-dione as antiproliferation agent
10/06/2005US20050222244 Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors
10/06/2005US20050222243 Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use
10/06/2005US20050222242 Process for preparing a dipeptidyl peptidase IV inhibitor and intermediates employed therein
10/06/2005US20050222240 COX-2 inhibitory activity; useful for the treatment of arthritis and other conditions due to inflammation; 4-[5-(4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-benzenesulfonamide
10/06/2005US20050222239 Pyrazole-amine compounds for the treatment of neurodegenerative disorders
10/06/2005US20050222238 Deuterated substituted pyrazolylbenzylsulfonamides and medicaments comprising said compounds
10/06/2005US20050222236 Viral polymerase inhibitors
10/06/2005US20050222235 Drugs for improving the prognosis of brain injury and a method of screening the same
10/06/2005US20050222234 Mucin production inhibitor
10/06/2005US20050222233 Preparing amorphous form of valsartan by precipitating amorphous valsartan from a solution of valsartan in a solvent selected from methyl ethyl ketone and ethyl acetate and recovering valsartan amorphous form without heating; use in treating hypertension
10/06/2005US20050222232 Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
10/06/2005US20050222231 2-Amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives; nervous system, psychological, and psychiatric disorders
10/06/2005US20050222230 3,4-diarylpyrazoles and their use in the therapy of cancer
10/06/2005US20050222228 Novel diazine derivatives
10/06/2005US20050222227 Oxazole-amine compounds for the treatment of neurodegenerative disorders
10/06/2005US20050222224 p53 Inhibitors and therapeutic use of the same
10/06/2005US20050222223 And oxazole sulfonamides: 3-(2-{1-[(4-Chloro-benzenesulfonyl)-(2,5-difluoro-phenyl)-amino]-ethyl}-thiazol-5-yl)-propionic acid; Alzheimer's disease, hereditary cerebral hemorrhage with amyloidosis, cerebral amyloid angiopathy, prion-mediated disease, inclusion body myositis, stroke, multiple sclerosis
10/06/2005US20050222222 1-[3-[2-[2-cyano-(S)-pyrrolidin-1-yl]-2-oxo-ethylamino]-1-oxo-propyl]-4-[bis-(4-fluorophenyl)methyl]piperazine; inhibiting dipeptidyl peptidase IV or for treating Type II diabetes
10/06/2005US20050222221 Cell differentiation, regeneration of pancreas epithelial cells to insulin producing beta cells; administering a dipeptidyl-peptidase activators
10/06/2005US20050222220 GSK-3 inhibitors
10/06/2005US20050222219 N-(1,3,4-thiadiazolyl)glycinamides, e.g., (S)-(6,8-Difluoro-1,2,3,4-tetrahydro-naphthalen-2-ylamino)-pentanoic acid [5-(1,1-dimethyl-but-3-enyl)-[1,3,4]thiadiazol-2-yl]-amide; treating diseases requiring inhibition of the production of A beta -peptide such as Alzheimer's disease
10/06/2005US20050222217 Agonists and antagonists of nicotinergic acetylcholine receptors of insects like fleas, lice and flies, on humans or animals; chloronicotinyl insecticides such as imidaclopridas veterinary medicine; collars; tags
10/06/2005US20050222215 Broadspectrum heterocyclic substituted phenyl containing sulfonamide hiv protease inhibitors
10/06/2005US20050222213 Alpha(trifluoromethyl-substituted aryloxy, arylamino, arylthio or arylmethyl)-trifluoromethyl-substituted phenylacetic acids and derivatives as antidiabetic agents
10/06/2005US20050222212 Non-peptide, reversible inhibitors of bacterial methionine aminopeptidases, e.g., 3-anilino-5-(thiophen-2-ylmethylthio)-1,2,4-triazole
10/06/2005US20050222211 S(-)rabeprazole compositions and methods
10/06/2005US20050222209 Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
10/06/2005US20050222207 Phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs
10/06/2005US20050222206 Pyridinoylpiperidines as 5-ht1f agonists
10/06/2005US20050222205 Treatment of pain with ifendropil
10/06/2005US20050222204 Therapy for obesity; using secondary amino compound; antidiabetic agents; irritable bowel syndrome; nausea, antidepressants, drug abuse
10/06/2005US20050222203 Nitrogen heterocycle biaryls for osteoporosis and other diseases
10/06/2005US20050222202 Free of N-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butyl]-6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone; prepared by reacting 6-hydroxy-3,4-dihydroquinolin-2(1H)-one with 5-(4-chlorobutyl)-1-cyclohexyl-1H-tetrazole; is at least 99% pure
10/06/2005US20050222201 such as 3-(2-chloro-4-quinolinyl)-2,5-dimethyl-1H-indole-1-acetic acid, used for treating respiratory system disorders and as inhibitors of G protein-coupled receptor chemoattractant homologous receptor expressed on lymphocyte cells (CRTH2)
10/06/2005US20050222200 4-(2,2-dichloro)-N-(quinolin-3-yl)benzamide; (1R,2R)2-methyl-N-(quinolin-3-yl)-4-(2-(trifluoromethyl)cyclopropyl)benzamide; inflammation-related conditions in mammals, arthritis, Parkinson's/Alzheimer's diseases, stroke, asthma; acute/chronic or neuropathic pain; VR1 agonist/antagonist
10/06/2005US20050222199 Process for the preparation of a hydrate of an antranilic acid derivative
10/06/2005US20050222198 Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment
10/06/2005US20050222197 Novel pyrazolopyridine derivatives as pharmaceutical agents
10/06/2005US20050222196 Azabicyclic-substituted fused heteroaryl compounds for the treatment of disease
10/06/2005US20050222195 administering bi-cyclic and mono-cyclic tautomers of 13,14-dihydro-15-keto-16,16-difluoro-prostaglandin E1 in triglyceride, for treating constipation without substantive side-effects, such as stomach ache
10/06/2005US20050222194 3-[p-(phenoxy, phenylthio, phenylsulfinyl, or phenylsulfonyl)benzyl]-quinolin-2(1H)-ones or 5--[p-(phenoxy, phenylthio, phenylsulfinyl, or phenylsulfonyl)benzyl]-pyrrolo[3,2,1-IJ]quinolin-4(4H)-ones; type E antagonists; analgesics, antipyretics, antiinflammatory agents; side effect reduction
10/06/2005US20050222192 Pyridoindolone derivatives substituted in the 3-position by a heterocyclic group, their preparation and their application in therapeutics
10/06/2005US20050222191 Solution formulations of sirolimus and its analogs for CAD treatment
10/06/2005US20050222190 1,4-bis-N-oxide azaanthracenediones and the use thereof
10/06/2005US20050222189 Oxa-and thiadiazoles and their use as metalloproteinase inhibitors
10/06/2005US20050222188 comprising hydrogenating with a hydrogen donor and a catalyst under reflux
10/06/2005US20050222187 A quaternary ammonium salts of 1-{2-(3'-chlorobiphenyl-4-yl)-2-oxoethyl}-4-(3-trifluoromethyl-phenyl)-1,2,3,6-tetrahydropyridine for treating neurodegenerative disorders; chemical synthesis; mixture with other active ingredients; Alzheimer's disease, cerebral edema, brain and nervous system disorders
10/06/2005US20050222186 Substituted diaminopyrimidines
10/06/2005US20050222185 Nucleoside derivatives and therapeutic uses therof
10/06/2005US20050222183 Combination of zd6474, an inhibitor of the vascular endothelial growth factor receptor, with radiotherapy in the treatment of cancer
10/06/2005US20050222182 Stabilized pharmaceutical compositions of halofuginone and other quinazolinone derivatives
10/06/2005US20050222181 Compounds in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3
10/06/2005US20050222180 Pharmacokinetic properties, including improved oral bioavailability, greater potency and extended effective drug biological half-life in vivo; inhibiting RNA-dependent RNA polymerase, infections
10/06/2005US20050222179 Adenosine receptor antagonists and methods of making and using the same
10/06/2005US20050222178 Process
10/06/2005US20050222177 Diseases with abnormal activation of the Abl, BCR-Abl, Bmx, CSK, TrkB, FGFR3, Fes, Lck, B-RAF, C-RAF, MKK6, alpha and beta SAPK2 kinases; antiproliferative; pyrrolo[2,3-d]pyrimidine-7-carboxylic acid [3-phenylcarbamoyl-phenyl]-amides and pyrrolo[3,2-c]pyridine analogs
10/06/2005US20050222176 Piperidinylamino-thieno[2,3-D] pyrimidine compounds
10/06/2005US20050222175 New piperidinylamino-thieno[2,3-D] pyrimidine compounds
10/06/2005US20050222172 Active ingredient in treating neurodegenerative disease, Alzheimer's disease caused by abnormal enzyme activity
10/06/2005US20050222171 Organic compounds
10/06/2005US20050222170 In combination with organic nitrate or nitric oxide donors or inhibitors of cyclic GMP metabolism; erectile dysfunction or female sexual dysfunction
10/06/2005US20050222169 Compositions and methods of treating infections
10/06/2005US20050222168 Beta-carboline derived guanidine alkaloids, tiruchenduramine
10/06/2005US20050222167 Amidation of 3-(acidinylamino)-5-methylolanilines with 5-[4-phenylpiperazin-1-yl(thio)carbonylamino]nicotinic acids and the product, which have antitumor activity and low toxicity.
1 ... 4514 4515 4516 4517 4518 4519 4520 4521 4522 4523 4524 4525 4526 4527 4528 4529 4530 4531 4532 4533 4534 ... 7860